论文部分内容阅读
目的 :探讨重组人脑利钠肽联合厄贝沙坦治疗充血性心力衰竭的临床疗效。方法 :将我院2012年1月~2014年12月收治的110例充血性心力衰竭患者平均分为两组,对照组采用厄贝沙坦治疗,研究组采用重组人脑利钠肽联合厄贝沙坦治疗。对比两组患者治疗1月后的超声心动图、血清生化指标及安全性。结果 :通过1月治疗后,研究组患者超声心动图指标明显优于对照组,血清内皮素-1(ET-1)、去甲肾上腺素(NE)、抗利尿激素(ADH)显著低于对照组,两组之间的不良反应发生率无统计学差异。结论 :重组人脑利钠肽联合厄贝沙坦可有效改善充血性心力衰竭患者的超声心动图与血清生化指标,且安全性良好,值得在临床实践中推广应用。
Objective: To investigate the clinical efficacy of recombinant human brain natriuretic peptide combined with irbesartan in the treatment of congestive heart failure. Methods: One hundred and ten patients with congestive heart failure admitted from January 2012 to December 2014 in our hospital were divided into two groups equally. The control group was treated with irbesartan. The study group was treated with recombinant human brain natriuretic peptide Sartan treatment. Echocardiography, serum biochemical parameters and safety were compared between the two groups after 1 month of treatment. Results: After treatment in January, the indexes of echocardiography in the study group were significantly better than those in the control group. The levels of ET-1, NE and ADH in the study group were significantly lower than those in the control group There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Recombinant human brain natriuretic peptide combined with irbesartan can effectively improve echocardiography and serum biochemical parameters in patients with congestive heart failure, and is safe and worthy of promotion in clinical practice.